Serum macrophage migration inhibition activity in patients with leprosy.
We have found that 26 of 54 (48%) untreated patients with leprosy had serum migration inhibitory activity, and that this was present in tuberculoid, borderline, and lepromatous forms of the disease. Patients with active recreational states; i.e., reversal reactions, Lucio's reaction, or erythema nodosum leprosum, were particularly apt to have this inhibitory activity. The prevalence of inhibitory activity did not vary significantly with treatment, dinitrochlorobenzene responsiveness, tuberculin responsiveness, or serum lysozyme levels.
D003622:Dapsone / Q000627:therapeutic use; D004137:Dinitrochlorobenzene; D006801:Humans; D006968:Hypersensitivity, Delayed; D007918:Leprosy / Q000188:drug therapy / Q000276:immunology*; D008263:Macrophage Migration-Inhibitory Factors / Q000032:analysis*; D008970:Molecular Weight; D009113:Muramidase / Q000097:blood; D011241:Prednisone / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use
D004137:Dinitrochlorobenzene; D008263:Macrophage Migration-Inhibitory Factors; D013792:Thalidomide; D003622:Dapsone; D009113:Muramidase; D011241:Prednisone